Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma

Dirk Rades, Lena Sehmisch, Stefan Janssen, Steven E. Schild

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.

Original languageEnglish (US)
Pages (from-to)6637-6640
Number of pages4
JournalAnticancer Research
Volume36
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Melanoma
Radiotherapy
Neoplasm Metastasis
Brain
Survival
Confidence Intervals
Multivariate Analysis
Therapeutics

Keywords

  • Brain metastases
  • Malignant melanoma
  • Prognoses
  • Treatment results
  • Whole-brain radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma. / Rades, Dirk; Sehmisch, Lena; Janssen, Stefan; Schild, Steven E.

In: Anticancer Research, Vol. 36, No. 12, 01.12.2016, p. 6637-6640.

Research output: Contribution to journalArticle

Rades, Dirk ; Sehmisch, Lena ; Janssen, Stefan ; Schild, Steven E. / Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma. In: Anticancer Research. 2016 ; Vol. 36, No. 12. pp. 6637-6640.
@article{7e7a4ec8273a4b3f983e48a572d1abfd,
title = "Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma",
abstract = "Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95{\%} confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95{\%} confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.",
keywords = "Brain metastases, Malignant melanoma, Prognoses, Treatment results, Whole-brain radiotherapy",
author = "Dirk Rades and Lena Sehmisch and Stefan Janssen and Schild, {Steven E.}",
year = "2016",
month = "12",
day = "1",
doi = "10.21873/anticanres.11271",
language = "English (US)",
volume = "36",
pages = "6637--6640",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma

AU - Rades, Dirk

AU - Sehmisch, Lena

AU - Janssen, Stefan

AU - Schild, Steven E.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.

AB - Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.

KW - Brain metastases

KW - Malignant melanoma

KW - Prognoses

KW - Treatment results

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85002377961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002377961&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11271

DO - 10.21873/anticanres.11271

M3 - Article

C2 - 27919995

AN - SCOPUS:85002377961

VL - 36

SP - 6637

EP - 6640

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -